Eli Lilly and Co

EMA's CHMP recommended Eli Lilly’s Omvoh for EU approval to treat moderately to severely active Crohn’s disease. Omvoh, an IL-23p19 antagonist, is already approved for ulcerative colitis in the US, Japan, and the EU. The recommendation is based on Phase III VIVID-1 trial outcomes, marking progress towards full EU regulatory endorsement.

Innovent Biologics and Eli Lilly announce a Distribution and Promotion Agreement for Jaypirca® (pirtobrutinib) in Mainland China. Innovent will handle importation, marketing, distribution, and promotion, while Lilly will manage R&D and post-market medical affairs. Jaypirca®, a non-covalent BTK inhibitor, is approved for treating relapsed or refractory mantle cell lymphoma in China and the U.S.

Innovent Biologics and Eli Lilly announce a Distribution and Promotion Agreement for Jaypirca® (pirtobrutinib) in Mainland China. Innovent will handle importation, marketing, distribution, and promotion, while Lilly will oversee R&D and post-market medical affairs. Jaypirca®, a non-covalent BTK inhibitor, is approved for treating mantle cell lymphoma patients previously treated with covalent BTK inhibitors.

Weight loss drugs like Ozempic, Wegovy, and Mounjaro, initially for diabetes, help users lose 15-20% of body weight by mimicking GLP-1 hormone. Despite promising reductions in obesity rates, studies show these drugs don't lower overall healthcare costs; in fact, medical expenses increase. The drugs don't address underlying appetite control issues, leading to weight regain post-use. They also cause muscle loss, potentially slowing metabolism.

© 2024 www.detroitnews.com

Viking Therapeutics and Summit Therapeutics stocks doubled in 2024. Analysts predict Viking could gain 166% to $125, and Summit 68% to $30 in 2025. Viking's VK2735, a weight loss drug, shows promising trial results. Summit's ivonescimab, a cancer therapy, outperforms Keytruda in trials.

Zealand Pharma and Eli Lilly are top weight-loss stock picks. Zealand's survodutide, in phase 3 trials, offers a unique mechanism. Eli Lilly's Zepbound, a blockbuster, sees $3B in manufacturing expansion. Both stocks have outperformed and show strong potential for continued growth.